First published online 5 January 2005
doi: 10.1242/dev.01596
Development 132, 553-563 (2005)
Published by The Company of Biologists 2005
Tbx5 and Tbx20 act synergistically to control vertebrate heart morphogenesis
Daniel D. Brown1,2,
Shauna N. Martz1,
Olav Binder1,
Sarah C. Goetz1,2,
Brenda M. J. Price3,
Jim C. Smith3 and
Frank L. Conlon1,2,*
1 Department of Genetics, Fordham Hall, UNC-Chapel Hill, Chapel Hill, NC
27599-3280, USA
2 Department of Biology, Fordham Hall, UNC-Chapel Hill, Chapel Hill, NC
27599-3280, USA
3 Wellcome Trust/Cancer Research UK Gurdon Institute of Cancer and Developmental
Biology and Department of Zoology, University of Cambridge, Tennis Court Road,
Cambridge CB2 1QR, UK

View larger version (77K):
[in a new window]
|
Fig. 5. TBX5 and TBX20 morphants display dramatic morphological defects.
Whole-mount in situ hybridization of cleared stage 36 embryos. (A-C)
ANF whole-mount in situ hybridization. (D-F) XTnIc
whole-mount in situ hybridization. (A,D) ControlMO. (B,E) TBX5MO and (C,F)
TBX20MO.
|
|

View larger version (47K):
[in a new window]
|
Fig. 9. Tbx5 and Tbx20 synergistically act to regulate cardiac
gene expression. (A-L) Embryos injected with the indicated morpholinos at the
one-cell stage. (A-D) Nkx2-5 whole-mount in situ hybridization. (E-H)
XANF whole-mount in situ hybridization. (I-L) XTnIc
whole-mount in situ hybridization. (A,E,I) ControlMO, (B,F,J) TBX5MO injected
at suboptimal dose, (C,G,K) TBX20MO injected at suboptimal dose, (D,H,L)
TBX5MO and TBX20MO injected in combination at suboptimal doses. All embryo
were cleared to reveal heart expression. (M) Statistics for embryos injected
with suboptimal doses of TBX5MO and TBX20MO in combination with each other or
with ControlMO. Hearts were judged as having defects if they displayed a
pericardial edema, an unlooped heart tube or reduction in cardiac mass.
|
|

View larger version (28K):
[in a new window]
|
Fig. 1. Tbx5 and Tbx20 morpholinos block translation of their
respective target proteins. (A) TBX5MO and TBX20MO positions relative to
Tbx5 and Tbx20 cDNA. (B) Inhibition of TBX5-V5 translation
in vitro by TBX5MO. TBX20MO and ControlMO serve as controls. Each reaction
contains 1 µg of Tbx5-V5 circular plasmid along with the indicated
amounts of MO. (C) Inhibition of TBX20-V5 translation in vitro by TBX20MO.
TBX5MO and ControlMO serve as controls. Each reaction contains 1 µg of
Tbx20-V5 circular plasmid along with the indicated amounts of MO. (D)
Inhibition of TBX5-V5 translation by TBX5MO in animal caps. TBX20MO and
ControlMO serve as controls. Probed with anti-V5 and re-probed with
anti-PTP1D/SHP2 as a loading control. Embryos injected with 2 ng mRNA and the
indicated amounts of MO. (E) Inhibition of TBX20-V5 translation by TBX20MO in
animal caps. TBX20MO and ControlMO serve as controls. Probed with anti-V5 and
re-probed with anti-PTP1D/SHP2 as a loading control. Embryos injected with 2
ng mRNA and the indicated amounts of MO.
|
|

View larger version (44K):
[in a new window]
|
Fig. 2. Tbx5 and Tbx20 are required for proper cardiogenesis.
(A-F) Morpholino-injected tadpoles at the indicated stages. Control morphant
embryos (A,D), TBX5 morphant embryos (B,E) and TBX20 morphant embryos (C,F).
Arrows indicate the heart region, arrowheads indicate the eye. (G) Chart
displaying the percentage of morphants surviving and displaying cardiac
abnormalities, as scored by the presence of an unlooped heart tube, a
reduction in cardiac mass and the presence of a pericardial edema.
|
|

View larger version (55K):
[in a new window]
|
Fig. 3. TBX5 and TBX20 morphants fail to undergo looping and chamber formation and
display reduced cardiac cell numbers. Cryosections of TBX5 and TBX20 morphant
hearts taken at the anterior (outflow), middle (ventricular) and posterior
(atrial) regions. (A-D) ControlMO, (E-H) TBX5MO and (I-L) TBX20MO. Sections
stained for tropomyosin (red), DAPI (blue) and cardiac actin (green). (D,H,L)
Same sections as B, F and J stained with cardiac actin. In the looped control
heart, the middle ventricular section also contains the atrium. (M) Mean
number of cells per heart obtained by cell counts of heart tissue in serial
sections derived from a minimum of three embryos.
|
|

View larger version (87K):
[in a new window]
|
Fig. 4. Cardiac specification is unaltered in TBX5 and TBX20 morphants. Whole-mount
in situ with Nkx2.5 on stage matched (A,D,G,J) ControlMO-, (B,E,H,K)
TBX5MO- or (C,F,I,L) TBX20MO-derived embryos.
|
|

View larger version (32K):
[in a new window]
|
Fig. 6. Tbx5 and Tbx20 are localized to the nucleus and can
activate transcription on the Nppa/ANF promoter. (A)
Schematic depicting the amino acid positions of the T-box domains of
Tbx5 and Tbx20. (B) Schematic of Rat
Nppa/ANF-luciferase reporter construct showing
T-box-binding site consensus sequences and their relative position within the
promoter relative to translation start site. (C-H) Transfected cells were
stained with anti-V5 (C,F; Cy2, green) for TBX5-V5 and TBX20-V5, and with
anti-phosphotyrosine (D,G; Cy3, red) to visualize cytoplasmic compartment.
Overlaid image of Cy2 and Cy3 staining (E,H). (I) Rat
ANF-luciferase co-transfected with a constant amount of
Tbx5 (100 ng) and increasing amounts of Tbx20 (25, 50, 100
and 500 ng) in 293T cells, and the level of transcriptional activation is
expressed as relative luciferase units based on average of three independent
experiments performed in triplicate.
|
|

View larger version (50K):
[in a new window]
|
Fig. 7. Tbx5 and Tbx20 are not required for the expression of
each other. Embryos injected at the one-cell stage with ControlMO, TBX5MO or
TBX20MO. (A,C) Whole-mount in situ hybridization showing Tbx5
expression. (B,D) Whole-mount in situ hybridization showing Tbx20
expression.
|
|
© The Company of Biologists Ltd 2005